Atlas Trials

Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

Clinical trial NCT05666804 · COMPLETED

Trial details

NCT number
NCT05666804
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Macular Polypoidal Choroidal Vasculopathy (PCV)
Start date
2023-02-06
Primary completion
2025-09-10
Enrollment
148

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.